Publications by authors named "M Chaves-Conde"
Article Synopsis
- Advanced head and neck squamous cell carcinoma (HNSCC) is challenging to treat, prompting research into combining immunotherapies like epacadostat (IDO inhibitor) with pembrolizumab (PD-1 inhibitor) for potential better outcomes compared to single treatments.
- The KEYNOTE-669/ECHO-304 clinical trial examined the effectiveness and safety of this combination versus pembrolizumab alone and the standard EXTREME regimen in patients with recurrent/metastatic HNSCC, with results cut off in January 2019 after early study enrollment cessation.
- Results showed varying objective response rates: 31% for the combination therapy, 21% for pembrolizumab alone, and 34% for EXTREME,
Article Synopsis
- * Recent results from the SUNLIGHT trial show promise for the TAS-102-bevacizumab combination, and new molecular targets in precision medicine are emerging for managing metastatic colorectal cancer.
- * Various treatment options such as anti-EGFR rechallenge, anti-HER2 therapies, and Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) are being explored, with discussions on sequencing these therapies for improved outcomes.
Mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs) are a heterogeneous group of malignant neoplasms that can settle in the gastroenteropancreatic tract. They are composed of a neuroendocrine (NE) and a non-NE component in at least 30% of each tumour. The non-NE component can include different histological combinations of glandular, squamous, mucinous and sarcomatoid phenotypes, and one or both of the components can be low-or high grade malignant.
View Article and Find Full Text PDFAppendiceal mucinous lesions' classification and nomenclature has been modified several times along the last decades, reflecting their great heterogeneity and making difficult to compare results and draw conclusions. Despite its nearby origin, appendiceal mucinous lesions have a distinctive behaviour compared to colorectal cancer, including their molecular and genetic markers. Due to their low frequency, their management is not well standardised.
View Article and Find Full Text PDFObjectives: The aim of this study was to confirm the efficacy of the ERBITAX scheme (paclitaxel 80 mg/m weekly and cetuximab 400 mg/m loading dose, and then 250 mg/m weekly) as first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) who are medically unfit for cisplatin-based (PT) chemotherapy.
Materials And Methods: This retrospective, non-interventional study involved 16 centers in Spain. Inclusion criteria were to have started receiving ERBITAX regimen from January 2012 to December 2018; histologically confirmed SCCHN including oral cavity, oropharynx, hypopharynx, and larynx; age ≥18 years; and platinum (PT) chemotherapy ineligibility due to performance status, comorbidities, high accumulated dose of PT, or PT refractoriness.